Alterity Therapeutics Ltd ADR(ATHE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:00 PM ET (Korea 10/28 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.9 | Insider Own | 4.67% | Shs Outstand | 19.1M | Perf Week | -6.75% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | -30.09% | Insider Trans | 5.64% | Shs Float | 18.2M | Perf Month | -36.86% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | - | Inst Own | 2.06% | Short Float | 0.21% | Perf Quarter | -50.23% |
| Income | -0.02B | P/S | - | EPS this Y | -225.68% | Inst Trans | 53.35% | Short Ratio | 1.94 | Perf Half Y | -51.75% |
| Sales | 0.00B | P/B | 1.35 | EPS next 5Y | - | ROA | -51.53% | Short Interest | 0.04M | Perf YTD | -28.25% |
| Book/sh | 1.63 | P/C | 1.63 | EPS past 3/5Y | 80.11% 66.1% | ROE | -55.71% | 52W High | -62.49% ($5.89) | Perf Year | -50.97% |
| Cash/sh | 1.35 | P/FCF | - | Sales past 3/5Y | - | ROIC | -53.83% | 52W Low | 9.95% ($2.01) | Perf 3Y | -10.89% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 96.65% | Gross Margin | - | Volatility(W/M) | 13.1% 10.63% | Perf 5Y | -82.03% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.3 | Perf 10Y | -92.68% |
| Dividend Ex-Date | - | Quick Ratio | 14.52 | EPS Q/Q | -155.28% | Profit Margin | - | RSI (14) | 25.41 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 14.52 | Sales Q/Q | - | SMA20 | -21.54% ($2.82) | Beta | 0.33 | Target Price | $18.43 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/28 | SMA50 | -39.31% ($3.64) | Rel Volume | 0.18 | Prev Close | $2.08 |
| Employees | 11 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 55.99% -87.55% | SMA200 | -44.72% ($4) | Avg Volume(3M) | 0.02M | Price | $2.21 |
| IPO | 2002/9/5 | Option/Short | No/Yes | Trades | 74 | Volume | 3,527 | Change | 6.25% |
🧬 This is a clinical-stage biotech company developing oral therapies that target pathological protein aggregation associated with neurodegenerative diseases. Headquartered in Australia, it trades in the U.S. as an American Depositary Receipt (ADR) and is a micro-cap drug developer focused on multiple system atrophy and Parkinson's-related disorders as its core indications.
Over the past 1 year, on the lower side
62% below its 1-year high.
Traded less than usual. That is 18% of its average volume.
ATHE has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -225.7% this year.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -82.0%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 2.1%.
Tap to view numbers
It ranks #428 of 594 in the industry
Based on market cap of $42M.
ANVS#426 Annovis Bio Inc $43M PER - 
SER#427 Serina Therapeutics Inc $42M PER - ATHE#428 Alterity Therapeutics Ltd ADR $42M PER - 
INMB#429 INmune Bio Inc $42M PER - 
GRDX#430 GridAI Technologies Corp $42M PER - 
FAQ
What kind of company is ATHE?
ATHE belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ATHE?
The market cap of ATHE is approximately $42M, ranking 4,928 within its sector.
What is the 52-week high and low for ATHE?
ATHE has recorded a 52-week high of $5.89 and a low of $2.01.
